Synthesis and In Vitro Analysis of Dual‐Functionalized Mesoporous Silica Nanoparticles for Targeted Theranosis of ER(+) Breast Cancer
Drug Development Research · 2025
DOI: 10.1002/ddr.70138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Garima Mann und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organization, Delhi, India. Hauptthemen laut MEDLINE: Silicon Dioxide, Breast Neoplasms, Nanoparticles, Receptors, Estrogen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: This study has been supported by the Defence Research and Development Organization, Ministry of Defence..
Abstract (Originalsprache)
Mesoporous silica nanoparticles have been extensively utilized for targeted drug delivery; the drugs are encapsulated in the pores, while the surface can be modified to make the nanoparticles target‐specific. The work presented here focuses on the development of multifunctional theranostic mesoporous silica nanoparticles with estrogen receptor‐positive [ER(+)] breast cancer as the target. The surface of the nanoparticles was dually functionalized to make the nanoparticles target‐specific using an estradiol derivative via a facile click reaction and to attach a 99m Tc complexing agent (DTPA) for SPECT imaging. The size of the spherical nanoparticles was 80–110 nm, and the nanosystem was subjected to various physicochemical analysis techniques. Mesoporous nanoparticles were loaded with tamoxifen, an FDA‐approved ER antagonist. Drug release at pH 5.8 was much more rapid than at physiological pH 7.4, a beneficial characteristic for controlled drug delivery at the tumor site. Cellular internalization and competitive binding studies indicated estradiol‐mediated preferential uptake by MCF‐7 cells. The nanocarrier exhibited good antiproliferative activity towards the ER(+) MCF 7 cells with a 92% decline in cellular viability in 48 h, whereas the cellular viability of the estrogen receptor‐negative [ER(−)] MDA‐MB‐231 cells remained > 60%. Thus, our results suggest a high theranostic potential of MSN‐Est for breast cancer management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organization, Delhi, India.
- Department of Chemistry, University of Delhi, Delhi, India.
- Centro de Nanociencias y Nanotecnología, Universidad Nacional Autónoma de México, Ensenada, Ensenada, Baja California, Mexico.
- Department of Chemistry, Graphic Era Hill University, Dehradun, Uttrakhand, India.
- Centro de Física Aplicada y Tecnología Avanzada, Universidad Nacional Autónoma de México, Juriquilla, Queretaro, Mexico.
ORCID-Profile: Garima Mann, Kanchan Chauhan, Anupriya Adhikari, Karla Juarez-Moreno, Nikhil Kumar, Anupama Datta
Förderung
- This study has been supported by the Defence Research and Development Organization, Ministry of Defence.
Zitieren
APA
Mann, G., Chauhan, K., Adhikari, A., Juarez-Moreno, K., Kumar, N., Daksh, S., Thirumal, M., & Datta, A. (2025). Synthesis and In Vitro Analysis of Dual‐Functionalized Mesoporous Silica Nanoparticles for Targeted Theranosis of ER(+) Breast Cancer. Drug Development Research. https://doi.org/10.1002/ddr.70138
Vancouver
Mann G, Chauhan K, Adhikari A, Juarez-Moreno K, Kumar N, Daksh S, et al. Synthesis and In Vitro Analysis of Dual‐Functionalized Mesoporous Silica Nanoparticles for Targeted Theranosis of ER(+) Breast Cancer. Drug Development Research. 2025. doi:10.1002/ddr.70138
BibTeX
@article{Mann2025,
author = {Mann, Garima and Chauhan, Kanchan and Adhikari, Anupriya and Juarez-Moreno, Karla and Kumar, Nikhil and Daksh, Shivani and Thirumal, Meganathan and Datta, Anupama},
title = {Synthesis and In Vitro Analysis of Dual‐Functionalized Mesoporous Silica Nanoparticles for Targeted Theranosis of ER(+) Breast Cancer},
journal = {Drug Development Research},
year = {2025},
doi = {10.1002/ddr.70138}
}
EUVIMED